ICD10 code of Danon disease and ICD9 code

Danon disease is classified under the ICD-10 code E75.249 (Other sphingolipidosis, unspecified) or sometimes tracked under broader cardiomyopathy codes, while it does not have a unique, dedicated ICD-9-CM code. Because Danon disease is a rare multisystem disorder, it is frequently coded based on its primary clinical manifestation, such as hypertrophic cardiomyopathy (ICD-10 I42.2).

What is the clinical classification of Danon disease?

Danon disease is a rare, X-linked dominant multisystem disorder characterized by the triad of cardiomyopathy, skeletal myopathy, and intellectual disability. Because it is a lysosomal storage disorder, it is often categorized within metabolic or genetic registries. While ICD-10 provides a specific code for other sphingolipidosis (E75.249), the lack of a unique, disease-specific ICD-9 code means that clinicians often use codes related to the patient’s most severe symptom, such as hypertrophic cardiomyopathy or glycogen storage disease type IIb, to ensure proper billing and medical record tracking for those living with Danon disease.

How is Danon disease diagnosed and managed?

Diagnosis of Danon disease is confirmed through genetic testing identifying a mutation in the LAMP2 gene located on the X chromosome. Because Danon disease follows an X-linked inheritance pattern, it primarily affects males with greater severity, though females can also present with significant cardiac symptoms. Clinical management requires a multidisciplinary team to address the progressive nature of the condition. Patients within our DiseaseMaps.org community often share experiences regarding the challenges of navigating these complex diagnostic paths.

What are the primary symptoms associated with Danon disease?

The clinical presentation of Danon disease can vary significantly between individuals. Most patients experience early-onset cardiac issues that progress to severe heart failure. Key features include:

• Cardiac: Hypertrophic cardiomyopathy, which is often severe and may require heart transplantation.


• Neurological: Intellectual disability, which can range from mild to moderate, and developmental delays.


• Muscular: Skeletal myopathy leading to weakness, typically in the proximal muscles.


• Ocular: Retinal pigmentary changes are frequently observed during ophthalmological examinations.

Is Danon disease hereditary?

Yes, Danon disease is a genetic condition caused by pathogenic variants in the LAMP2 gene. It is inherited in an X-linked dominant manner. This means that a mother with the mutation has a 50% chance of passing it to her children, while an affected father will pass the mutation to all of his daughters but none of his sons. Due to the genetic nature of Danon disease, genetic counseling is strongly recommended for all families to understand recurrence risks and the implications for extended family members.

Next steps

• Consult with a cardiologist specializing in inherited cardiomyopathies to establish a baseline cardiac assessment.


• Request a referral to a clinical geneticist to confirm the LAMP2 mutation and discuss family screening.


• Connect with the 4 community members on DiseaseMaps.org who have firsthand experience managing the daily realities of Danon disease.


• Monitor the NIH GARD website for updates on clinical trials and emerging therapeutic research for lysosomal storage disorders.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: Danon disease overview and clinical features.


• Orphanet: ORPHA1393 (Danon disease) classification and diagnostic criteria.


• OMIM (Online Mendelian Inheritance in Man): Entry #300257 (Lysosome-associated membrane protein 2; LAMP2).


• PubMed: Recent literature reviews on the pathophysiology and management of LAMP2-deficient cardiomyopathy.